

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Diabetes: Innovations, Outcomes and Personalized Therapies (X3)

Scientific Organizers: Philip J. Larsen, Melina Claussnitzer and Tina Vilsbøll

Supported by the Directors' Fund

Unraveling the Secrets of Kidney Disease (X4)

Scientific Organizers: Katalin Susztak, Caroline Fox and Masaomi Nangaku

March 3-7, 2019 • Whistler Conference Centre • Whistler, British Columbia, Canada

Supported by the Directors' Fund

Abstract & Scholarship Deadline: November 6, 2018 / Abstract Deadline: December 4, 2018 / Discounted Registration Deadline: January 11, 2019

SUNDAY, MARCH 3

Arrival and Registration

MONDAY, MARCH 4

Welcome and Keynote Address (X4)

Harold I. Feldman, University of Pennsylvania School of Medicine, USA

Genetic and Environmental Factors Controlling the Development and Progression of Kidney Disease; Lessons Learnt from the CRIC (Chronic Renal Insufficiency Cohort) Study

State of the Union for Diabetes Care anno 2019: What Should We Expect from a Stellar Novel Diabetes Drug? (X3)

Peter Stein[†], U.S. Food and Drug Administration, USA
End Point Expectations for Novel Diabetes Drugs: Is Glucocentric HbA1c Focus still the Right Treatment Goal or should we rather Pay Attention to other End Points?

Bernard Zinman, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Canada

Learnings from Empa-Reg Outcome and LEADER

Tina Vilsbøll, Steno Diabetes Center Copenhagen, Denmark
How to Demonstrate Medical Value for Diabetes Drugs Fast and Convincingly

Short Talk(s) Chosen from Abstracts

Podocyte Diseases (X4)

Friedhelm Hildebrandt, Howard Hughes Medical Institute and Boston Children's Hospital, Harvard Medical School, USA
Monogenic causes of Podocyte Loss Reveal Targets for Personalized Treatment

John Cijiang He, Icahn School of Medicine at Mount Sinai, USA
Mechanism of Podocyte Dysfunction

Stuart J. Shankland, University of Washington, USA
Understanding Podocyte Regeneration

Short Talk(s) Chosen from Abstracts

Keynote Address (X3)

Leif C. Groop, Lund University, Sweden
Diabetes Comes in Different Flavors: On the Heterogeneity of Diabetes - Time for Reclassification of a Disease

Workshop and Panel Discussion (X3)

Short Talks Chosen from Abstracts

Diabetes and Its Many Phenotypes (X3)

Michael P. Snyder, Stanford University School of Medicine, USA
Power of Personalized Genomic Medicine: How to Improve Diabetes Care

Tai E. Shyong, National University of Singapore, Singapore
Ethnically Determined Diabetes Variants (Asian Diabetes)

Juleen R. Zierath, Karolinska Institutet, Sweden
The Role of Diet and Exercise in Modifying the Epigenetic Landscape in Type 2 Diabetes

Short Talk Chosen from Abstracts

Immune Injury (X4)

Ali Gharavi, Columbia University Medical Center, USA
Genetics of IgA Nephropathy/Role of Complement

Martin Pollak, Beth Israel Deaconess Medical Center, USA
Inflammation and APOL1-associated Kidney Disease

David J. Salant, Boston University School of Medicine, USA
PLA2R and Membranous Nephropathy

Matthias Kretzler, University of Michigan, USA
Progression Pathways in CKD

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, MARCH 5

Keynote Address (Joint)

Mark I. McCarthy, University of Oxford, UK
Can We Actually Learn Anything about Diabetes Risk from GWAS? Population-based Genetics

Genetics and Epigenetics of Diabetes and Complications (Joint)

Anna Köttgen, University Freiburg Medical Center, Germany
Genetics of Kidney Disease and Metabolite Traits

Melina Claussnitzer, Harvard Medical School, Beth Israel Deaconess Medical Center, USA
Type 2 Diabetes and its Comorbidities: The Journey from GWAS to Disease Mechanism

Katalin Susztak, University of Pennsylvania, USA
Finding the G(ene) in GWAS for Kidney Disease

Short Talk(s) Chosen from Abstracts

Deciphering Cellular Function of Target Tissues of Relevance for Diabetes (X3)

Marcelo Nobrega, University of Chicago, USA
Experimental Dissection of the Cellular and Organismal Effects of T2D Genes

Kenichiro Furuyama, University of Geneva, Switzerland
Conversion of Human non-β-Cells into Insulin Producers

Chad A. Cowan, Harvard University, USA
Investigating Metabolic Disease with Human Pluripotent Stem Cells

Short Talk Chosen from Abstracts

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Diabetes: Innovations, Outcomes and Personalized Therapies (X3)

Scientific Organizers: Philip J. Larsen, Melina Claussnitzer and Tina Vilsbøll

Supported by the Directors' Fund

Unraveling the Secrets of Kidney Disease (X4)

Scientific Organizers: Katalin Susztak, Caroline Fox and Masaomi Nangaku

March 3-7, 2019 • Whistler Conference Centre • Whistler, British Columbia, Canada

Supported by the Directors' Fund

Abstract & Scholarship Deadline: November 6, 2018 / Abstract Deadline: December 4, 2018 / Discounted Registration Deadline: January 11, 2019

Tubule Injury and Regeneration (X4)

Benjamin D. Humphreys, Washington University School of Medicine, USA

Mapping Cell States to Understand Human Diabetic Nephropathy and Chronic Kidney Disease using Single Cell and Single Nucleus RNA-Seq

Masaomi Nangaku, University of Tokyo School of Medicine, Japan
The Role of Hypoxia and HIF in Tubule Injury

Mark Douglas Okusa, University of Virginia, USA
Immune Injury in AKI

Short Talk Chosen from Abstracts

Poster Session 2

WEDNESDAY, MARCH 6

Complications of Diabetes (Joint)

Susan Quaggin, Northwestern University, USA
The Role of Endothelial Cell Injury in Diabetic Kidney Disease

Matthew D. Breyer, Eli Lilly and Company, USA
Therapeutic Targeting of the Endothelium in Diabetes

Donald Kohan, University of Utah Health Center, USA
Endothelin Receptors Antagonists in DKD: SONAR and Beyond

Farhad Danesh, University of Texas MD Anderson Cancer Center, USA

Podocyte and Mitochondrial Dysfunction in Diabetes

Short Talk(s) Chosen from Abstracts

Omics Stuff and Profiling (X3)

Christopher B. Newgard, Duke University Medical Center, USA
Biochemical Phenotyping of Metabolic Syndrome

Cecilia Lindgren, Oxford University, UK
Identifying Metabolic Cross-Trait Signatures Using UK Biobank

Hans-Ulrich Häring, Eberhard-Karls University Tübingen, Germany
Insulin Sensitization: Improving more than Glycemic Control

Short Talk Chosen from Abstracts

Endothelial Dysfunction in CKD (X4)

Ananth Karumanchi[†], Beth Israel Deaconess Medical Center, USA
VEGF and Angiogenic Factors in Preeclampsia and CKD

Janos Peti-Peterdi, University of Southern California, USA
The Physiological and Pathophysiological Regulation of Glomerular Blood Flow

Hiddo Lambers Heerspink, University Medical Center Groningen, Netherlands
SGLT2 Inhibitors and Diabetic Nephropathy and Non-Diabetic CKD

Short Talk Chosen from Abstracts

Speaker to be Announced

Mitchell A. Lazar, Perelman School of Medicine, University of Pennsylvania, USA

Epigenomic Regulation of Metabolism

Maike Sander, University of California, San Diego, USA
Epigenetic Adaptation in the beta Cell

Evan D. Rosen, Beth Israel Deaconess Medical Center, Harvard University, USA

Epigenetic Variability in Insulin Resistant States

Short Talk(s) Chosen from Abstracts

Precision Medicine (X4)

Jonathan Himmelfarb, University of Washington, USA
Kidney on Chip for Drug Development

Eugene Park Rhee, Massachusetts General Hospital, USA
Metabolomics To Understand Kidney Function

Rahul Satija, New York Genome Center, USA
Single Cell Immune Sequencing in Lupus Nephritis

Short Talk(s) Chosen from Abstracts

Workshop (X4)

Short Talks Chosen from Abstracts

Metabolic Surgery (X3)

Geltrude Mingrone[†], King's College London, UK
Metabolic Improvements after Bariatric By-Pass Surgery: Solely Ascribable to Caloric Deficit or Does an Elusive Factor Assist?

Lee M. Kaplan, Massachusetts General Hospital, USA
Variability of Response and Prediction of Outcome

Filip K. Knop, Gentofte Hospital, University of Copenhagen, Denmark
The Liver-alpha Cell Axis: A New Endocrine System with (Patho)Physiologic and Pharmacologic Implications

Philip J. Larsen, Sanofi, Germany
Can We Translate Bariatric Surgery into Equi-Efficacious Pharmacotherapy

Novel Approaches for Drug Discovery (X4)

Alan R. Shuldiner, Regeneron Pharmaceuticals, Inc, USA
Drug Discovery 2.0, the Use of Human Knock-Out Project

Caroline Fox, Merck Research Labs, USA
Using Genetics to Drive Drug Discovery

Alex Bell, Ionis Pharmaceuticals, USA
RNA Therapeutics for Kidney Disease

Stephanie Cherqui, University of California, San Diego, USA
Stem Cell and Gene Therapy for Cystonosis

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X3)

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Diabetes: Innovations, Outcomes and Personalized Therapies (X3)

Scientific Organizers: Philip J. Larsen, Melina Claussnitzer and Tina Vilsbøll

Supported by the Directors' Fund

Unraveling the Secrets of Kidney Disease (X4)

Scientific Organizers: Katalin Susztak, Caroline Fox and Masaomi Nangaku

March 3-7, 2019 • Whistler Conference Centre • Whistler, British Columbia, Canada

Supported by the Directors' Fund

Abstract & Scholarship Deadline: November 6, 2018 / Abstract Deadline: December 4, 2018 / Discounted Registration Deadline: January 11, 2019

Poster Session 3

THURSDAY, MARCH 7

Epigenomics of T2D (X3)

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
(X4)

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Diabetes: Innovations, Outcomes and Personalized Therapies (X3)

Scientific Organizers: Philip J. Larsen, Melina Claussnitzer and Tina Vilsbøll

Supported by the Directors' Fund

Unraveling the Secrets of Kidney Disease (X4)

Scientific Organizers: Katalin Susztak, Caroline Fox and Masaomi Nangaku

March 3-7, 2019 • Whistler Conference Centre • Whistler, British Columbia, Canada

Supported by the Directors' Fund

Abstract & Scholarship Deadline: November 6, 2018 / Abstract Deadline: December 4, 2018 / Discounted Registration Deadline: January 11, 2019

FRIDAY, MARCH 8

Departure